Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis

Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.
No abstract available

Publication types

  • Letter
  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Angiotensin Receptor Antagonists / adverse effects
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • Betacoronavirus / pathogenicity
  • COVID-19
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / metabolism
  • Coronavirus Infections / mortality
  • Coronavirus Infections / virology
  • Host-Pathogen Interactions
  • Humans
  • Pandemics
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / metabolism
  • Pneumonia, Viral / mortality
  • Pneumonia, Viral / virology
  • Renin-Angiotensin System / drug effects*
  • Risk Factors
  • SARS-CoV-2
  • Treatment Outcome

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Antiviral Agents

Supplementary concepts

  • COVID-19 drug treatment